Your browser doesn't support javascript.
loading
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
Maruki, Taketomo; Nomoto, Hidetoshi; Iwamoto, Noriko; Yamamoto, Kei; Kurokawa, Masami; Iwatsuki-Horimoto, Kiyoko; Yamayoshi, Seiya; Suzuki, Yutaka; Kawaoka, Yoshihiro; Ohmagari, Norio.
Affiliation
  • Maruki T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Nomoto H; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: hnomoto@hosp.ncgm.go.jp.
  • Iwamoto N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Yamamoto K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kurokawa M; Laboratory Testing Department, National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwatsuki-Horimoto K; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Yamayoshi S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Suzuki Y; Department of Computational Biology and Medical Sciences, The University of Tokyo, Tokyo, Japan.
  • Kawaoka Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Pandemic Preparedness, Infection and Advanced Research Center, The University of Tokyo, Tokyo, Japan; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
J Infect Chemother ; 30(8): 793-795, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38242284
ABSTRACT
The management of persistent symptomatic coronavirus disease 2019 (COVID-19) infections in immunocompromised patients remains unclear. Here, we present the first case of successful antiviral therapy (nirmatrelvir/ritonavir and remdesivir) in combination with intravenous immunoglobulin (IVIg) in a patient who had received CD20 depleting therapy for follicular lymphoma and experienced recurrent COVID-19 relapses. After the patient received IVIg treatment, the viral load decreased without recurrence. Subsequently, it was found that the anti-spike antibody titer in the administered immunoglobulin was high at 9528.0 binding antibody units/mL. Our case highlights the potential of combination therapy with selective IVIg and antiviral drugs for relapsed immunocompromised COVID-19 patients who have received CD20 depleting therapy.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Lymphoma, Follicular / Immunoglobulins, Intravenous / Immunocompromised Host / Ritonavir / Alanine / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Limits: Humans / Male / Middle aged Language: En Journal: J Infect Chemother Journal subject: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Lymphoma, Follicular / Immunoglobulins, Intravenous / Immunocompromised Host / Ritonavir / Alanine / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Limits: Humans / Male / Middle aged Language: En Journal: J Infect Chemother Journal subject: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Type: Article Affiliation country: Japan